{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:15:45Z","timestamp":1792289745222,"version":"4.4.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,22]]},"DOI":"10.7759\/cureus.19822","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T05:51:31Z","timestamp":1637646691000},"source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of Cilnidipine (L\/N-type Calcium Channel Blocker) in Treatment of Hypertension: A Meta-Analysis of Randomized and Non-randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Rabindra Nath","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Langade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"More","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Revandlkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Birla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.11909\/j.issn.1671-5411.2019.03.014","article-title":"2018 Chinese Guidelines for prevention and treatment of hypertension: A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension","volume":"16","year":"2019","unstructured":"2018 Chinese Guidelines for prevention and treatment of hypertension. A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol. 2019, 16:182-241. 10.11909\/j.issn.1671-5411.2019.03.014","journal-title":"J Geriatr Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12112","article-title":"A two-for-one bargain: using cilnidipine to treat hypertension and its comorbidities","volume":"15","author":"Iyer RP","year":"2013","unstructured":"Iyer RP, Lindsey ML, Chilton RJ. A two-for-one bargain: using cilnidipine to treat hypertension and its comorbidities. J Clin Hypertens (Greenwich). 2013, 15:455-7. 10.1111\/jch.12112","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref3","article-title":"Hypertensive and cardiovascular profiles of a newly synthesized dihydropyridine derivative 2-methoxyethyl (E)-3-phenyl-2-propen-1-yl(6)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl) pyridine-3,5-dicarboxylate (FRC-8653)","volume":"44","author":"Ikeda K","year":"1992","unstructured":"Ikeda K, Hosino M, Iida H, Ohnishi H. Hypertensive and cardiovascular profiles of a newly synthesized dihydropyridine derivative 2-methoxyethyl (E)-3-phenyl-2-propen-1-yl(6)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl) pyridine-3,5-dicarboxylate (FRC-8653). Pharmacometrics. 1992, 44:433-42.","journal-title":"Pharmacometrics"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/10641960902822492","article-title":"Cilnidipine inhibits the sympathetic nerve activity and improves baroreflex sensitivity in patients with hypertension","volume":"31","author":"Kishi T","year":"2009","unstructured":"Kishi T, Hirooka Y, Konno S, Sunagawa K. Cilnidipine inhibits the sympathetic nerve activity and improves baroreflex sensitivity in patients with hypertension. Clin Exp Hypertens. 2009, 31:241-9. 10.1080\/10641960902822492","journal-title":"Clin Exp Hypertens"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.69.119","article-title":"Inhibitory effect of cilnidipine on pressor response to acute cold stress in spontaneously hypertensive rats","volume":"69","author":"Hosono M","year":"1995","unstructured":"Hosono M, Hiruma T, Watanabe K, Hayashi Y, Ohnishi H, Takata Y, Kato H. Inhibitory effect of cilnidipine on pressor response to acute cold stress in spontaneously hypertensive rats. Jpn J Pharmacol. 1995, 69:119-25. 10.1254\/jjp.69.119","journal-title":"Jpn J Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-5198(19)47033-9","article-title":"Changes in heart rate and plasma catecholamine levels accompanied with hypotesive action of calcium channel blockers in conscious SHR","volume":"67","author":"Hiruma T","year":"1995","unstructured":"Hiruma T, Hosono M, Watanabe K, Hayashi Y, Ohnishi H. Changes in heart rate and plasma catecholamine levels accompanied with hypotesive action of calcium channel blockers in conscious SHR. Jpn J Pharmacol. 1995, 67:267. 10.1016\/S0021-5198(19)47033-9","journal-title":"Jpn J Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12042","article-title":"The effects of the L\/N-type calcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension: results from ACHIEVE-ONE","volume":"15","author":"Kario K","year":"2013","unstructured":"Kario K, Ando S, Kido H, et al.. The effects of the L\/N-type calcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension: results from ACHIEVE-ONE. J Clin Hypertens (Greenwich). 2013, 15:133-42. 10.1111\/jch.12042","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2010.01.048","article-title":"Dual actions of cilnidipine in human internal thoracic artery: inhibition of calcium channels and enhancement of endothelial nitric oxide synthase","volume":"141","author":"Fan L","year":"2011","unstructured":"Fan L, Yang Q, Xiao XQ, et al.. Dual actions of cilnidipine in human internal thoracic artery: inhibition of calcium channels and enhancement of endothelial nitric oxide synthase. J Thorac Cardiovasc Surg. 2011, 141:1063-9. 10.1016\/j.jtcvs.2010.01.048","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.56.225","article-title":"Prolonged inhibition of vascular contraction and calcium influx by the novel 1,4-dihydropyridine calcium antagonist cinaldipine (FRC-8653)","volume":"56","author":"Yoshimoto R","year":"1991","unstructured":"Yoshimoto R, Dohmoto H, Yamada K, Goto A. Prolonged inhibition of vascular contraction and calcium influx by the novel 1,4-dihydropyridine calcium antagonist cinaldipine (FRC-8653). Jpn J Pharmacol. 1991, 56:225-9. 10.1254\/jjp.56.225","journal-title":"Jpn J Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1248\/bpb1978.15.547","article-title":"In vitro and ex vivo Ca-antagonistic effect of 2-methoxyethyl(E)-3-phenyl-2-propen-1-yl(+\/-)-1,4-dihydro-2,6-dimethyl- 4-(3- nitrophenyl)pyridine-3,5-dicarboxylate (FRC-8653), a new dihydropyridine derivative","volume":"15","author":"Hosono M","year":"1992","unstructured":"Hosono M, Iida H, Ikeda K, et al.. In vitro and ex vivo Ca-antagonistic effect of 2-methoxyethyl(E)-3-phenyl-2-propen-1-yl(+\/-)-1,4-dihydro-2,6-dimethyl- 4-(3- nitrophenyl)pyridine-3,5-dicarboxylate (FRC-8653), a new dihydropyridine derivative. J Pharmacobiodyn. 1992, 15:547-53. 10.1248\/bpb1978.15.547","journal-title":"J Pharmacobiodyn"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/2231-4040.154543","article-title":"Comparison of amlodipine with cilnidipine on antihypertensive efficacy and incidence of pedal edema in mild to moderate hypertensive individuals: A prospective study","volume":"6","author":"Adake P","year":"2015","unstructured":"Adake P, Somashekar HS, Mohammed Rafeeq PK, Umar D, Basheer B, Baroudi K. Comparison of amlodipine with cilnidipine on antihypertensive efficacy and incidence of pedal edema in mild to moderate hypertensive individuals: A prospective study. J Adv Pharm Technol Res. 2015, 6:81-5. 10.4103\/2231-4040.154543","journal-title":"J Adv Pharm Technol Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2012.96","article-title":"Renoprotective and antioxidant effects of cilnidipine in hypertensive patients","volume":"35","author":"Soeki T","year":"2012","unstructured":"Soeki T, Kitani M, Kusunose K, et al.. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients. Hypertens Res. 2012, 35:1058-62. 10.1038\/hr.2012.96","journal-title":"Hypertens Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.22159\/ajpcr.2021.v14i1.39962","article-title":"Evaluation of renoprotective effect of cilnidipine in patients with mild to moderate hypertension and type 2 diabetes mellitus - a prospective study","volume":"14","author":"Ramya R","year":"2021","unstructured":"Ramya R, Shahan OM, Anakha K. Evaluation of renoprotective effect of cilnidipine in patients with mild to moderate hypertension and type 2 diabetes mellitus - a prospective study. Asian J Pharm Clin Res. 2021, 14:144-146. 10.22159\/ajpcr.2021.v14i1.39962","journal-title":"Asian J Pharm Clin Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/10641963.2016.1235183","article-title":"Blood pressure control with cilnidipine treatment in Japanese post-stroke hypertensive patients: the CA-ATTEND study","volume":"39","author":"Aoki S","year":"2017","unstructured":"Aoki S, Hosomi N, Nezu T, et al.. Blood pressure control with cilnidipine treatment in Japanese post-stroke hypertensive patients: the CA-ATTEND study. Clin Exp Hypertens. 2017, 39:225-34. 10.1080\/10641963.2016.1235183","journal-title":"Clin Exp Hypertens"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2174\/187152912801823165","article-title":"The efficacy and safety of cilnidipine on mild to moderate essential hypertension: a systematic review and meta-analysis of randomized controlled trials in Chinese patients","volume":"12","author":"Xu G","year":"2012","unstructured":"Xu G, Wu H, Du B, Qin L. The efficacy and safety of cilnidipine on mild to moderate essential hypertension: a systematic review and meta-analysis of randomized controlled trials in Chinese patients. Cardiovasc Hematol Disord Drug Targets. 2012, 12:56-62. 10.2174\/187152912801823165","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement","volume":"354","author":"Moher D","year":"1999","unstructured":"Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet. 1999, 354:1896-1900. 10.1016\/s0140-6736(99)04149-5","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.21.215","article-title":"Comparison between cilnidipine and nisoldipine with respect to effects on blood pressure and heart rate in hypertensive patients","volume":"21","author":"Minami J","year":"1998","unstructured":"Minami J, Ishimitsu T, Higashi T, Numabe A, Matsuoka H. Comparison between cilnidipine and nisoldipine with respect to effects on blood pressure and heart rate in hypertensive patients. Hypertens Res. 1998, 21:215-9. 10.1291\/hypres.21.215","journal-title":"Hypertens Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.33.6.1447","article-title":"Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension","volume":"33","author":"Sakata K","year":"1999","unstructured":"Sakata K, Shirotani M, Yoshida H, Nawada R, Obayashi K, Togi K, Miho N. Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension. 1999, 33:1447-52. 10.1161\/01.hyp.33.6.1447","journal-title":"Hypertension"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-822700053-4","article-title":"Cilnidipine, the N- and L-type calcium channel antagonist, reduced on 24-h urinary catecholamines and C-peptide in hypertensive non-insulin-dependent diabetes mellitus","volume":"44(3)","author":"Takeda S","year":"1999","unstructured":"Takeda S, Ueshiba H, Hattori Y, et al.. Cilnidipine, the N- and L-type calcium channel antagonist, reduced on 24-h urinary catecholamines and C-peptide in hypertensive non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1999, 44(3):197-205. 10.1016\/s0168-822700053-4","journal-title":"Diabetes Res Clin Pract"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.24.377","article-title":"Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis","volume":"24","author":"Rose GW","year":"2001","unstructured":"Rose GW, Kanno Y, Ikebukuro H, et al.. Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. Hypertens Res. 2001, 24:377-83. 10.1291\/hypres.24.377","journal-title":"Hypertens Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.27.379","article-title":"Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases","volume":"27","author":"Kojima S","year":"2004","unstructured":"Kojima S, Shida M, Yokoyama H. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res. 2004, 27:379-85. 10.1291\/hypres.27.379","journal-title":"Hypertens Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/10641960500298558","article-title":"Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine","volume":"27","author":"Tsuchihashi T","year":"2005","unstructured":"Tsuchihashi T, Ueno M, Tominaga M, Kajioka T, Onaka U, Eto K, Goto K. Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine. Clin Exp Hypertens. 2005, 27:583-91. 10.1080\/10641960500298558","journal-title":"Clin Exp Hypertens"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3282c2fa62","article-title":"Renal and vascular protective effects of cilnidipine in patients with essential hypertension","volume":"25","author":"Morimoto S","year":"2007","unstructured":"Morimoto S, Yano Y, Maki K, Iwasaka T. Renal and vascular protective effects of cilnidipine in patients with essential hypertension. J Hypertens. 2007, 25:2178-83. 10.1097\/HJH.0b013e3282c2fa62","journal-title":"J Hypertens"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002623","article-title":"Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease","volume":"72","author":"Fujita T","year":"2007","unstructured":"Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int. 2007, 72:1543-9. 10.1038\/sj.ki.5002623","journal-title":"Kidney Int"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2009.01299.x","article-title":"Effect of cilnidipine vs losartan on cerebral blood flow in hypertensive patients with a history of ischemic stroke: a randomized controlled trial","volume":"121","author":"Hong KS","year":"2010","unstructured":"Hong KS, Kang DW, Bae HJ, et al.. Effect of cilnidipine vs losartan on cerebral blood flow in hypertensive patients with a history of ischemic stroke: a randomized controlled trial. Acta Neurol Scand. 2010, 121:51-7. 10.1111\/j.1600-0404.2009.01299.x","journal-title":"Acta Neurol Scand"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32833d01dd","article-title":"A new-generation N\/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker","volume":"28","author":"Konoshita T","year":"2010","unstructured":"Konoshita T, Makino Y, Kimura T, et al.. A new-generation N\/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker. J Hypertens. 2010, 28:2156-60. 10.1097\/HJH.0b013e32833d01dd","journal-title":"J Hypertens"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2009.11","article-title":"Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease","volume":"32","author":"Abe M","year":"2009","unstructured":"Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease. Hypertens Res. 2009, 32:270-5. 10.1038\/hr.2009.11","journal-title":"Hypertens Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3109\/10641961003667914","article-title":"Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection","volume":"32","author":"Miwa Y","year":"2010","unstructured":"Miwa Y, Tsuchihashi T, Ohta Y, et al.. Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection. Clin Exp Hypertens. 2010, 32:400-5. 10.3109\/10641961003667914","journal-title":"Clin Exp Hypertens"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-012-0274-1","article-title":"L\/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease","volume":"28","author":"Abe M","year":"2013","unstructured":"Abe M, Maruyama N, Suzuki H, Inoshita A, Yoshida Y, Okada K, Soma M. L\/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. Heart Vessels. 2013, 28:480-9. 10.1007\/s00380-012-0274-1","journal-title":"Heart Vessels"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms140816866","article-title":"L\/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease","volume":"14","author":"Kanaoka T","year":"2013","unstructured":"Kanaoka T, Tamura K, Wakui H, et al.. L\/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease. Int J Mol Sci. 2013, 14:16866-81. 10.3390\/ijms140816866","journal-title":"Int J Mol Sci"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.4103\/0971-4065.151764","article-title":"Reduction of microalbuminuria in type-2 diabetes mellitus with angiotensin-converting enzyme inhibitor alone and with cilnidipine","volume":"25","author":"Singh VK","year":"2015","unstructured":"Singh VK, Mishra A, Gupta KK, Misra R, Patel ML, Shilpa. Reduction of microalbuminuria in type-2 diabetes mellitus with angiotensin-converting enzyme inhibitor alone and with cilnidipine. Indian J Nephrol. 2015, 25:334-9. 10.4103\/0971-4065.151764","journal-title":"Indian J Nephrol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2015\/12702.6754","article-title":"An open label parallel group study to assess the effects of amlodipine and cilnidipine on pulse wave velocity and augmentation pressures in mild to moderate essential hypertensive patients","volume":"9","author":"Pathapati RM","year":"2015","unstructured":"Pathapati RM, Rajashekar ST, Buchineni M, Meriga RK, Reddy CB, Kumar KP. An open label parallel group study to assess the effects of amlodipine and cilnidipine on pulse wave velocity and augmentation pressures in mild to moderate essential hypertensive patients. J Clin Diagn Res. 2015, 9:FC13-6. 10.7860\/JCDR\/2015\/12702.6754","journal-title":"J Clin Diagn Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-016-0796-z","article-title":"Long-term effects of L- and N-type calcium channel blocker on uric acid levels and left atrial volume in hypertensive patients","volume":"31","author":"Masaki M","year":"2016","unstructured":"Masaki M, Mano T, Eguchi A, et al.. Long-term effects of L- and N-type calcium channel blocker on uric acid levels and left atrial volume in hypertensive patients. Heart Vessels. 2016, 31:1826-33. 10.1007\/s00380-016-0796-z","journal-title":"Heart Vessels"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.14740\/cr494w","article-title":"Effects of cilnidipine on heart rate and uric acid metabolism in patients with essential hypertension","volume":"7","author":"Das A","year":"2016","unstructured":"Das A, Kumar P, Kumari A, Chandra S, Gari M, Singh N, Dey D. Effects of cilnidipine on heart rate and uric acid metabolism in patients with essential hypertension. Cardiol Res. 2016, 7:167-72. 10.14740\/cr494w","journal-title":"Cardiol Res"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3329\/bjms.v15i3.22536","article-title":"Comparison of the effects of L-type calcium channel antagonist Amlodipine with L\/N-type calcium channel antagonist Cilnidipine on blood pressure, heart rate, proteinuria and lipid profile in hypertensive patients","volume":"15","author":"Singal KK","year":"2016","unstructured":"Singal KK, Singal N, Gupta A, et al.. Comparison of the effects of L-type calcium channel antagonist Amlodipine with L\/N-type calcium channel antagonist Cilnidipine on blood pressure, heart rate, proteinuria and lipid profile in hypertensive patients. Bangladesh J Med Sci. 2016, 15:460. 10.3329\/bjms.v15i3.22536","journal-title":"Bangladesh J Med Sci"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12987","article-title":"Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial","volume":"71","author":"Hwang YC","year":"2017","unstructured":"Hwang YC, Yoon KH, Cha BS, et al.. Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial. Int J Clin Pract. 2017, 71:e12987. 10.1111\/ijcp.12987","journal-title":"Int J Clin Pract"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.24304\/kjcp.2020.30.4.259","article-title":"Comparison of usage patterns and outcomes by dual type calcium channel blockers in patients with chronic kidney disease","volume":"30","author":"Oh MR","year":"2020","unstructured":"Oh MR, Ahn HL, Choi S, La HO. Comparison of usage patterns and outcomes by dual type calcium channel blockers in patients with chronic kidney disease. Korean J Clin Pharm. 2020, 30:259-63. 10.24304\/kjcp.2020.30.4.259","journal-title":"Korean J Clin Pharm"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6653851","article-title":"Effects of L-\/N-type calcium channel blockers on angiotensin II-renin feedback in hypertensive patients","volume":"2020","author":"Kawabata Y","year":"2020","unstructured":"Kawabata Y, Soeki T, Ito H, et al.. Effects of L-\/N-type calcium channel blockers on angiotensin II-renin feedback in hypertensive patients. Int J Hypertens. 2020, 2020:6653851. 10.1155\/2020\/6653851","journal-title":"Int J Hypertens"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14218","article-title":"Clinical significance of nocturnal home blood pressure monitoring and nocturnal hypertension in Asia","volume":"23","author":"Fujiwara T","year":"2021","unstructured":"Fujiwara T, Hoshide S, Tomitani N, et al.. Clinical significance of nocturnal home blood pressure monitoring and nocturnal hypertension in Asia. J Clin Hypertens (Greenwich). 2021, 23:457-66. 10.1111\/jch.14218","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31919-5","article-title":"Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19\u00b71 million participants","volume":"389","year":"2017","unstructured":"Worldwide trends in blood pressure from 1975 to 2015. a pooled analysis of 1479 population-based measurement studies with 19\u00b71 million participants. Lancet. 2017, 389:37-55. 10.1016\/S0140-6736(16)31919-5","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension Global Hypertension Practice Guidelines","volume":"75","author":"Unger T","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, et al.. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020, 75:1334-57. 10.1161\/HYPERTENSIONAHA.120.15026","journal-title":"Hypertension"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton PK","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al.. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018, 71:1269-324. 10.1161\/HYP.0000000000000066","journal-title":"Hypertension"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams B","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al.. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018, 39:3021-104. 10.1093\/eurheartj\/ehy339","journal-title":"Eur Heart J"},{"key":"ref44","unstructured":"Hypertension in adults. diagnosis and management. (2019). Accessed: November 11, 2021: https:\/\/www.nice.org.uk\/guidance\/ng136."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2018.02.022","article-title":"Hypertension Canada's 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children","volume":"34","author":"Nerenberg KA","year":"2018","unstructured":"Nerenberg KA, Zarnke KB, Leung AA, et al.. Hypertension Canada's 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol. 2018, 34:506-25. 10.1016\/j.cjca.2018.02.022","journal-title":"Can J Cardiol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-019-0284-9","article-title":"The Japanese Society of Hypertension Guidelines for the management of hypertension (JSH 2019)","volume":"42","author":"Umemura S","year":"2019","unstructured":"Umemura S, Arima H, Arima S, et al.. The Japanese Society of Hypertension Guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019, 42:1235-481. 10.1038\/s41440-019-0284-9","journal-title":"Hypertens Res"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.11203","article-title":"Could 130\/80 mm Hg Be Adopted as the Diagnostic Threshold and Management Goal of Hypertension in Consideration of the Characteristics of Asian Populations?","volume":"71","author":"Kario K","year":"2018","unstructured":"Kario K, Wang JG. Could 130\/80 mm Hg Be Adopted as the Diagnostic Threshold and Management Goal of Hypertension in Consideration of the Characteristics of Asian Populations?. Hypertension. 2018, 71:979-84. 10.1161\/HYPERTENSIONAHA.118.11203","journal-title":"Hypertension"},{"key":"ref48","article-title":"Hypertension management: an update","volume":"3","author":"Nguyen Q","year":"2010","unstructured":"Nguyen Q, Dominguez J, Nguyen L, Gullapalli N. Hypertension management: an update. Am Health Drug Benefits. 2010, 3:47-56.","journal-title":"Am Health Drug Benefits"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)03307-9","article-title":"Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs results of prospectively designed overviews of randomised trials","volume":"355","author":"Neal B","year":"2000","unstructured":"Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs results of prospectively designed overviews of randomised trials. Lancet. 2000, 355:1955-1964. 10.1016\/s0140-6736(00)03307-9","journal-title":"Lancet"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson K","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, et al.. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008, 359:2417-28. 10.1056\/NEJMoa0806182","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian AV","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al.. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003, 42:1206-52. 10.1161\/01.HYP.0000107251.49515.c2","journal-title":"Hypertension"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.2174\/157340206776877370","article-title":"New generation calcium channel blockers in hypertensive treatment","volume":"2","author":"Ozawa Y","year":"2006","unstructured":"Ozawa Y, Hayashi K, Kobori H. New generation calcium channel blockers in hypertensive treatment. Curr Hypertens Rev. 2006, 2:103-11. 10.2174\/157340206776877370","journal-title":"Curr Hypertens Rev"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.11909\/j.issn.1671-5411.2017.01.006","article-title":"New generations of dihydropyridines for treatment of hypertension","volume":"14","author":"Wang AL","year":"2017","unstructured":"Wang AL, Iadecola C, Wang G. New generations of dihydropyridines for treatment of hypertension. J Geriatr Cardiol. 2017, 14:67-72. 10.11909\/j.issn.1671-5411.2017.01.006","journal-title":"J Geriatr Cardiol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.4082\/kjfm.2012.33.6.330","article-title":"Blood pressure variability and its management in hypertensive patients","volume":"33","author":"Choi HJ","year":"2012","unstructured":"Choi HJ. Blood pressure variability and its management in hypertensive patients. Korean J Fam Med. 2012, 33:330-5. 10.4082\/kjfm.2012.33.6.330","journal-title":"Korean J Fam Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.04.023","article-title":"Evaluation of the differences in the effects of antihypertensive drugs on blood pressure variability by 24-hour ambulatory blood pressure monitoring in chronic cerebrovascular disease","volume":"24","author":"Nishioka R","year":"2015","unstructured":"Nishioka R, Kinoshita S, Shiibashi M, et al.. Evaluation of the differences in the effects of antihypertensive drugs on blood pressure variability by 24-hour ambulatory blood pressure monitoring in chronic cerebrovascular disease. J Stroke Cerebrovasc Dis. 2015, 24:1848-54. 10.1016\/j.jstrokecerebrovasdis.2015.04.023","journal-title":"J Stroke Cerebrovasc Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/77509-efficacy-of-cilnidipine-ln-type-calcium-channel-blocker-in-treatment-of-hypertension-a-meta-analysis-of-randomized-and-non-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:30:54Z","timestamp":1707507054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/77509-efficacy-of-cilnidipine-ln-type-calcium-channel-blocker-in-treatment-of-hypertension-a-meta-analysis-of-randomized-and-non-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":55,"URL":"https:\/\/doi.org\/10.7759\/cureus.19822","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,22]]}}}